The company said the layoffs are part of a cost-reduction plan that aims to initially cut annual operating expenses by $1.7 million.

The restructuring and job cuts are expected to save the firm more than $70 million annually. 

The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.

The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.

The firm said that it planned to lay off its oncology sales team in order to focus on women's health, despite launching an oncology business unit last spring. 

In October, Roche reported the tissue diagnostics business contributed 8 percent to diagnostics sales in the first nine months of 2016.

The firm's CEO Ramji Srinivasan said the layoffs would help focus the company on developing relationships with clinicians and medical providers.

In November, the company said it was selling off its biomedical commercialization and marketing services business in order to focus on its diagnostic offerings.

The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.

Johnson & Johnson announced that it would be cutting about 3,000 jobs from its medical devices section.


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.